Outsmarting cancer by exploiting DNA repair flaws
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
List view / Grid view
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
A new cancer therapy combines multiple treatment strategies into a single graphene oxide-based nanocomposite. It uses bacterial components to enhance immune response and scalability, creating a powerful and cost-effective approach to tackling tumours.
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and…
A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals.
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
Researchers at Mount Sinai have created a computational tool that predicts effective drug combinations, providing a faster and more cost-efficient method for identifying potential treatments for complex diseases like cancer.
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.